Aetna | GenomeWeb


The test differentiates benign thyroid nodules from cancerous ones.

NEW YORK (GenomeWeb) – CardioDx today announced that Aetna has established a clinical policy for the Corus CAD gene expression test for coronary artery disease.

Insurer Aetna last month released a clinical policy bulletin providing an assessment of various available molecular-based cancer diagnostics and markers.

While Working with FDA, 23andMe Offers Customers No Timeline for Reporting Health-related Results

NEW YORK (GenomeWeb News) – The University of South Florida will use a $2.8 million grant from the National Institutes of Health to partner with Aetna and patient advocates to study how genetic testing for breast cancer risk can impact clinical decisions made by patients and doctors.

NEW YORK (GenomeWeb News) – Aetna this week issued a clinical policy bulletin suggesting that it may soon begin covering non-invasive prenatal DNA tests for Down syndrome.

"AlloMap molecular expression testing is considered medically necessary as a non-invasive method of determining the risk of rejection in heart transplant recipients between one and five years post transplant," Anthem wrote in an updated medical policy.

The decision means that "Aetna has decided to pay for AlloMap as a matter of policy," an XDx spokesperson said. Prior to the policy decision, "Aetna would require medical justification for each test to consider whether or not to pay" for it.


In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.